Currently, there are 119.56M common shares owned by the public and among those 100.98M shares have been available to trade.
The company’s stock has a 5-day price change of 4.46% and -18.66% over the past three months. APLS shares are trading -52.29% year to date (YTD), with the 12-month market performance down to -42.09% lower. It has a 12-month low price of $26.28 and touched a high of $73.80 over the same period. APLS has an average intraday trading volume of 2.11 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.99%, -10.27%, and -36.19% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares accounts for 94.00% of the company’s 119.56M shares outstanding.
It has a market capitalization of $3.57B and a beta (3y monthly) value of 0.88. The earnings-per-share (ttm) stands at -$2.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.16% over the week and 4.28% over the month.
Earnings per share for the fiscal year are expected to increase by 70.32%, and 110.27% over the next financial year. EPS should grow at an annualized rate of 33.30% over the next five years, compared to -13.70% over the past 5-year period.
Looking at the support for the APLS, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on October 25, 2024, with the firm’s price target at $25. Scotiabank was of a view on October 16, 2024 that the stock is Sector Outperform, while Piper Sandler gave the stock Neutral rating on May 31, 2024, issuing a price target of $46. Jefferies on their part issued Buy rating on February 05, 2024.
